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Abstract
Background: Cyclic vomiting syndrome (CVS), which is defined by recurrent stereotypical episodes of nausea and
vomiting, is a relatively-common disabling condition that is associated with migraine headache and mitochondrial
dysfunction. Co-enzyme Q10 (Co-Q) is a nutritional supplement that has demonstrated efficacy in pediatric and
adult migraine. It is increasingly used in CVS despite the complete lack of studies to demonstrate its value in
treatment
Methods: Using an Internet-based survey filled out by subjects with CVS or their parents, the efficacy, tolerability
and subject satisfaction in CVS prophylaxis were queried. Subjects taking Co-Q (22 subjects) were compared
against those taking amitriptyline (162 subjects), which is the general standard-of-care.
Results: Subjects/parents reported similar levels of efficacy for a variety of episode parameters (frequency, duration,
number of emesis, nausea severity). There was a 50% reduction in at least one of those four parameters in 72% of
subjects treated with amitriptyline and 68% of subjects treated Co-Q. However, while no side effects were reported
on Co-Q, 50% of subjects on amitriptyline reported side effects (P = 5 × 10
-7), resulting in 21% discontinuing
treatment (P = 0.007). Subjects/parents considered the benefits to outweigh the risks of treatment in 47% of cases
on amitriptyline and 77% of cases on Co-Q (P = 0.008).
Conclusion: Our data suggest that the natural food supplement Co-Q is potentially efficacious and tolerable in the
treatment of CVS, and should be considered as an option in CVS prophylaxis. Our data would likely be helpful in
the design of a double-blind clinical trial.
Background
Cyclic vomiting syndrome (CVS) is defined as recurrent
identical episodes of nausea and vomiting, with the
absence of these symptoms between episodes [1]. Prior
to the advent of successful therapy, CVS was in most
cases a disabling condition. Episodes of nausea and
vomiting are generally severe and often require intrave-
nous fluid therapy for dehydration. Frequent and pro-
longed school or work absences lead to academic or
work disability. CVS is apparently common, being pre-
sent in about 2% of Scottish [2] and Western Australian
[3] school children.
CVS is generally believed to be a variant of migraine
based on overlapping symptoms such as headache, nau-
sea, and photophobia. There is also frequent progression
of CVS to migraine headache, and a very high preva-
lence of migraine among close relatives of CVS patients
[4]. Furthermore, CVS and migraine respond to many of
the same medications including amitriptyline, cyprohep-
tadine, propranolol and triptans. Amitriptyline (Elavil®),
a tricyclic “antidepressant” is the most widely prescribed
prophylactic medication used for the treatment of CVS.
Response rates vary from 52-73% in open-label [5,6] and
subject recall-based [4,7] studies in children and adults.
In a recent consensus statement on management, ami-
triptyline was recommended as the first-line treatment
choice for CVS prophylaxis in patients age 5 years and
older [1]. * Correspondence: rboles@chla.usc.edu
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known as ubiquinone, has been gaining in popularity
among CVS patient groups. Co-Q is a commonly-used
dietary supplement that is widely available in retail set-
tings. Co-Q is a naturally-occurring steroid-derived
hydrophobic compound that is present in all organisms
and essentially all food sources. Co-Q serves as the elec-
tron shuttle between complexes 1 or 2 and complex 3
of the mitochondrial respiratory chain [8]. It is thus
essential for energy metabolism. Humans can manufac-
ture this compound but often do so in inadequate quan-
tities, with the remainder obtained from the diet.
Physicians and other health care providers are increas-
ingly recommending Co-Q for the treatment of a wide
variety of conditions, including migraine [9], heart fail-
ure [10], statin treatment [11], neurodegenerative condi-
tions [12], and primary inborn errors of mitochondrial
energy metabolism [13].
Mitochondrial dysfunction is hypothesized to be a fac-
tor in the pathogenesis of both CVS and migraine head-
ache based upon studies utilizing
31P-MRS [14] in
migraine, and in both conditions by decreased respira-
tory complex enzymology [15-17], disease-associated
mitochondrial DNA (mtDNA) sequence variants
[18-23], and preferential maternal inheritance [4,24-27].
mtDNA is exclusively inherited from the mother. Three
reasons prompted us to study whether Co-Q has effi-
cacy in CVS prophylaxis: 1) demonstrated efficacy of
Co-Q in migraine prophylaxis; 2) its increasingly popu-
lar usage in CVS; and 3) the association of both condi-
tions with mitochondrial dysfunction.
In this retrospective study, we compare the efficacy,
tolerability and patient satisfaction of Co-Q with the
current standard-of-care in CVS therapy: amitriptyline.
Methods
The study was advertised by the Cyclic Vomiting Syn-
drome Association (CVSA), a patient/family and profes-
sional led organization over a one-year period.
Recruitment was conducted by means of newsletters,
the CVSA website, e-mails to members and associated
physicians, and by word of mouth. Individuals given a
diagnosis of CVS by a health care professional, as
attested to by the subject/parent by survey, were invited
to participate in this study by completing an approxi-
mately 30-minute Internet-based survey (Survey Mon-
key). There was the option of completing the identical
survey on paper. Subjects remained anonymous, and all
aspects of this study were approved by the Childrens
Hospital Los Angeles Institutional Review Board.
Efficacy was queried in terms of four different vomit-
ing episode-based parameters: episode frequency, epi-
sode duration, number of emeses, and nausea severity.
A reduction of at least 50% in each parameter was
scored as positive and any lesser response as negative.
T h ec o m p o u n dm e a s u r eo f“episode improvement” was
scored as positive if at least one of the above four para-
meters were scored as positive. The data was reviewed
in terms of efficacy and tolerability on low (<0.5 mg/kg/
day), medium, and high (≥1.0 mg/kg/day) dosage ami-
triptyline, and for low and high (≥10 mg/kg/day or ≥
300 mg in a patient ≥ 30 kg) dosage Co-Q. The data
were also reviewed in terms of the child (<12 years),
adolescent and adult (≥18 years) onset of stereotypical
vomiting episodes. However, there were insufficient
numbers of adolescent-onset subjects in order to fully
characterize this group, and thus child- and adolescent-
onset data were combined in order to create a “pedia-
tric-onset” group. Chi square or Fisher exact tests were
used as appropriate. Statistics were performed by Win-
STAT Statistics for Windows, Kalmia Co. Inc., Cam-
bridge, MA, and by custom-made software.
Results
A total of 385 subjects completed the survey, of which
18 were excluded for the absence of a health profes-
sional-assigned diagnosis, and 13 for failure to meet
both the Rome III [28] and NASPGHAN [1] diagnostic
criteria for CVS based upon survey responses. Among
the 347 subjects remaining, 277 and 82 reported experi-
ence with amitriptyline and with Co-Q, respectively.
The final tally was 249 subjects for amitriptyline and 32
subjects for Co-Q after subtraction of 22 subjects who
had started on both compounds at the same time, and
63 subjects that had started on Co-Q and/or amitripty-
line and L-carnitine together. In both groups, 14 sub-
jects were tried on both therapies at different times, and
data on both are recorded.
Subjects reported treatment with a variety of different
dosages of amitriptyline and Co-Q, yet no dose-response
relationship or trend was evident. Furthermore, no rela-
tionship or trends were noted in regards to the age of
onset of vomiting episodes with either therapy. One
potential exception was a possible trend in a reduction
of episode frequency by Co-Q in pediatric-onset (<18
years; 10/17) but not in adult-onset (1/5) CVS (P =
0.15). Thus, data for all dosages and ages were com-
bined for statistical analyses.
In the compound measure of episode improvement,
there was no difference reported between the therapies,
with amitriptyline scoring positive in 72% and Co-Q in
68% (odds ratio = 1.2, 95% confidence interval 0.5-3.0).
Furthermore, similar rates of response with both thera-
pies were noted with all four episode parameters (Table
1).
Side effects were frequently reported with amitripty-
line (50%), and not recorded with Co-Q (P = 5 × 10
-7)
(Table 1). Among all subjects treated with amitriptyline,
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Page 2 of 521% discontinued (42/198) the drug because of side
effects. None of the 28 patients stopped Co-Q because
of side effects (P = 0.007). Queried as to whether the
efficacy justified the side effects (Table 1), those taking
Co-Q reported a significantly higher patient satisfaction
than did those taking amitriptyline (77% responding as
positive vs. 47%, P = 0.008, odds ratio = 3.6, 95% confi-
dence interval = 1.2-10). However, when asked if they
would recommend the agent to a relative or friend, the
difference vanishes (positive responses: amitriptyline
62%, Co-Q 64%). Overall, there was a potential trend
that subjects were more likely to remain on Co-Q versus
on amitriptyline at the time of the survey (77% v. 62%,
odds ratio 2.0, 95% confidence interval 0.75-5.2).
Discussion
CVS generally results in severe discomfort, dehydration
and disability, and despite prophylactic therapy substan-
tial numbers of patients continue to suffer from
repeated vomiting episodes. Our result of 72% efficacy
(defined by compound measure) in those taking prophy-
lactic amitriptyline agrees with the 52 to 73% efficacy
rates reported in four previous studies [4-7]. This result
also supports the overall validity of our on-line survey
methodology. Our data is also consistent with our own
clinical experience, in that overall efficacy is good (72%),
yet side effects are frequent (50%), and often result in
discontinuation of treatment (21%). Overall, approxi-
mately half (47%) of 134 subjects taking amitriptyline
reported that the benefits outweighed the side effects of
treatment. Furthermore, our data regarding the preven-
tative treatment of CVS with Co-Q is consistent with
our clinical experience, in that overall efficacy is good
(69%), with side effects being rare (0/22). Three-quarters
(77%) of subjects taking Co-Q reported that the benefits
outweighed the side effects, a significantly higher por-
tion than that with amitriptyline.
There are substantial child versus adult-related dif-
ferences in clinical CVS, such as longer and more fre-
quent episodes and more severe inter-episodic nausea
Table 1 Efficacy, tolerability and patient satisfaction of co-enzyme Q10 and amitriptyline in the treatment of cyclic
vomiting syndrome
Amitriptyline Co-enzyme Q10
Pediatric Onset
1
<18 y
Adult Onset ≥18
y
All
Subjects
Pediatric Onset
1
<18 y
Adult Onset ≥18
y
All
Subjects
Episode Frequency
2 62/113 26/49 88/162 10/17 1/5 11/22
55% 53% 54% 59% 20% 50%
Episode Duration
2 59/112 19/43 78/155 5/16 3/6 8/22
53% 44% 50% 31% 50% 36%
Number of Emesis
2 52/110 6/16 70/154 6/16 2/4 8/20
47% 41% 45% 38% 50% 40%
Nausea Severity
2 47/111 21/46 68/157 7/18 4/7 11/25
42% 46% 43% 39% 57% 40%
Episode Improvement
3 88/123 39/54 127/177 12/18 5/7 17/25
72% 72% 72% 67% 71% 68%
Side Effects Reported 72/139 30/63 102/202 0/20 0/8 0/28
52% 48% 50% 0% 0% 0%
Discontinued Therapy Due to Side
Effects
29/137 13/61 42/198 0/20 0/8 0/28
21% 21% 21% 0% 0% 0%
Subject Statement of Risks V.
Benefits
4
49/94 14/40 63/134 13/16 4/6 17/22
52% 35% 47% 81% 67% 77%
Subjects’ Recommendation
5 65/103 23/39 88/142 12/19 4/6 16/25
63% 59% 62% 63% 67% 64%
Subject on Therapy at Time of
Survey
68/111 30/48 98/159 14/19 6/7 20/26
61% 63% 62% 74% 86% 77%
1The number of adolescent-onset cases was small, so the data were combined with the child-onset data.
2Proportion reporting a 50% reduction in this parameter
3Proportion reporting a 50% reduction in at least one of the above four parameters
4“Do you believe that the improvement you receive of [inset treatment name], if any, justified the side effects that you experienced?” - proportion answering as
“yes, strongly” or “yes”, as opposed to “sort of equal/not sure”, “no” or “no, strongly”.
5“Would you recommend [inset treatment name] to a friend or relative with CVS?”–proportion answering as per
4above.
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Page 3 of 5among adults [29]. Furthermore, a strong association
with the 16519T and 3010A mtDNA polymorphisms
was noted in child-onset (< age 12 years), but not in
adult-onset (≥18 years) cases [30]. Although the num-
bers of subjects in some categories were small, overall
efficacy rates for both amitriptyline (70% v. 72%) and
Co-Q (71% v. 71%) were very similar among subjects
with child (<12 years) and adult (≥18 years) onset,
respectively. Thus, our data do not suggest that the
choice of either treatment should differ between pedia-
tric or adult patients.
The limitations of this study are the subjective nat-
ure of retrospective subject/parent-completed ques-
tionnaires, the lack of validation data for our
questionnaire, the lack of a proof of a physician-con-
firmed diagnosis of CVS, the self-selection bias in
Internet questionnaire studies, the relatively small
number of subjects reporting treatment with Co-Q,
and the wide range of treatment durations, dosages,
and in the case of Co-Q, brands and preparations (gel
capsules, liquids, tablets, etc.) utilized. Interestingly,
both amitriptyline and Co-Q seem to affect different
parameters in different people, including episode fre-
quency, episode duration,n u m b e ro fe m e s e s ,a n d
severity of nausea. Neither therapy appears to affect
t h ep r o d r o m e( d a t an o ts h o w n ) .T h i si n f o r m a t i o ni s
important in the design of future prospective clinical
trials in that complex end points for efficacy are
needed. The failure to find a dose-response is expected
as only the highest dosage attempted was queried, and
thus the high-dose group may contain treatment fail-
ures that are not recorded as failures on lower doses.
The authors’ clinical practice for treatment of CVS
with Co-Q is 10 mg/kg/day divided bid, up to 200 mg
bid (either in liquid or gel capsule formulation). It also
includes obtaining a blood Co-Q level in the case of
an inadequate response, and increasing the dose for
blood levels less than 3 mg/L. Additional mitochon-
drial-targeted dietary supplements have also been used
to prevent CVS attacks including L-carnitine, which
has demonstrated efficacy in CVS in one small open-
label study [31] (authors’ practice: 100 mg/kg/day
d i v i d e dB I D ,u pt oo n eg r a mB I Do rT I D ) ,a n dr i b o f l a -
vin, which has demonstrated efficacy in migraine head-
ache [32] (authors’ practice: 100-400 mg/day, or one
“B100” tablet a day). Anecdotally, in the authors’ prac-
tice while some CVS patients respond well to cofactor
therapy alone, many patients require drug therapy
(generally amitriptyline) in addition. While this combi-
nation may have synergy based on anecdotal observa-
tions, the numbers of subjects in the current study are
inadequate to address this question. This is another
question for a prospective clinical trial.
Conclusions
Our data suggest that the naturally-occurring food sup-
plement Co-Q (ubiquinone) has potential therapeutic
efficacy and excellent tolerability in the treatment of
CVS. This data would likely be helpful in the design of
a double-blind, prospective clinical trial, which is needed
to definitively determine the appropriate role of Co-Q in
CVS therapy. However, given the suggestion of efficacy,
excellent tolerability, high patient satisfaction, and rela-
tively low out-of-pocket costs (adult dose costs $15-20
U.S. per month from many discount stores), health care
providers may want to consider it as an low-risk thera-
peutic option in this disabling condition.
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